Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Payload diversification: a key step in the development of antibody–drug conjugates
Louise Conilh, Lenka Sadílková, Warren Viricel, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 108

Showing 26-50 of 108 citing articles:

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
Aleksei Kondrashov, Surendra Sapkota, Aditya Sharma, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2160-2160
Open Access | Times Cited: 18
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 6
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 14
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Giovanni Tonon, Flavio Rizzolio, Fabiano Visentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8651-8651
Open Access | Times Cited: 5
Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development
Qi Ma, Puro Durga, Frederick X.C. Wang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104057-104057
Closed Access | Times Cited: 4
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches
Shabnam Eghbali, Thatcher Heumann
Cancers (2025) Vol. 17, Iss. 2, pp. 236-236
Open Access
Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models
Virginia Metrangolo, Mylan Blomquist, Ananya Dutta, et al.
Science Advances (2025) Vol. 11, Iss. 3
Open Access
Camptothecin: a key building block in the design of anti-tumor agents
Bowen Liu, Lei Yao
Future Medicinal Chemistry (2025), pp. 1-4
Closed Access
Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates
Young‐Ho Oh, Dao T. T. An, Jaebeom Park, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130114-130114
Open Access
The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy
Huihui Guo, Hongsheng Xie, Yuanyuan Huang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Cancer-targeting drug conjugates drives a new era in precise cancer treatment
Jia Deng, Jianbin Shi, Dan Li, et al.
Chinese Chemical Letters (2025), pp. 110960-110960
Closed Access
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trails
Zhaohui Huang, Xinyu Li, Xin Zhou, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Reinventing chemotherapy
Bruce A. Chabner, Jacob Gehri, Beatrix Thompson
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets
Panagiotis Ntellas, Avani Athauda, Kemmyo Sugiyama, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 8, pp. 100154-100154
Closed Access
Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates
Qian-Qing Yin, Yanlong Zhang, Xueqing Xie, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy
Yanchen Li, Jin Wang, Tingting Liu, et al.
Bioconjugate Chemistry (2025)
Closed Access
Machine Learning for Predicting the Drug-to-Antibody Ratio (DAR) in the Synthesis of Antibody–Drug Conjugates (ADCs)
Luca Angiolini, Fabrizio Manetti, Ottavia Spiga, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access
Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
Zhiwen Fu, Chen Gao, Ting Wu, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107778-107778
Open Access | Times Cited: 12
ANTIBODY-DRUG CONJUGATES IN TRIPLE NEGATIVE BREAST CANCER
Merve Keskinkılıç, Ruth Sacks
Clinical Breast Cancer (2024) Vol. 24, Iss. 3, pp. 163-174
Closed Access | Times Cited: 4
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
Tao Chen, Jieyi Deng, Yongli Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
Jiazheng Yu, Mingyang Li, Xiandong Liu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116522-116522
Open Access | Times Cited: 4
Antibody drug conjugates in the clinic
Edidiong Udofa, Disha Sankholkar, Samir Mitragotri, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 6
Open Access | Times Cited: 4
Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics
Arya Bhushan, Preeti Misra
Current Oncology Reports (2024) Vol. 26, Iss. 10, pp. 1224-1235
Closed Access | Times Cited: 4
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Aditi Jain, Alan Barge, Christopher N. Parris
Oncogene (2024)
Open Access | Times Cited: 4

Scroll to top